HK1219228A1 - 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 - Google Patents

雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 Download PDF

Info

Publication number
HK1219228A1
HK1219228A1 HK16107282.4A HK16107282A HK1219228A1 HK 1219228 A1 HK1219228 A1 HK 1219228A1 HK 16107282 A HK16107282 A HK 16107282A HK 1219228 A1 HK1219228 A1 HK 1219228A1
Authority
HK
Hong Kong
Prior art keywords
triptolide
weight
oil
composition
sodium
Prior art date
Application number
HK16107282.4A
Other languages
English (en)
Chinese (zh)
Inventor
安金華
安金华
何衛國
何卫国
約翰‧
约翰‧M‧费德勒
‧費德勒
约翰‧H‧马瑟
‧馬瑟
Original Assignee
制药创源有限公司
迈洛克斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 制药创源有限公司, 迈洛克斯有限公司 filed Critical 制药创源有限公司
Publication of HK1219228A1 publication Critical patent/HK1219228A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16107282.4A 2013-03-15 2014-03-15 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药 HK1219228A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794926P 2013-03-15 2013-03-15
US61/794,926 2013-03-15
PCT/US2014/030041 WO2014145303A1 (en) 2013-03-15 2014-03-15 Intravenous emulsions of triptolide as immunomodulators and anticancer agents i

Publications (1)

Publication Number Publication Date
HK1219228A1 true HK1219228A1 (zh) 2017-03-31

Family

ID=51537944

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107282.4A HK1219228A1 (zh) 2013-03-15 2014-03-15 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药

Country Status (7)

Country Link
US (1) US20160038454A1 (https=)
EP (1) EP2968140A4 (https=)
JP (1) JP2016515530A (https=)
CN (1) CN105263475A (https=)
HK (1) HK1219228A1 (https=)
TW (1) TWI597071B (https=)
WO (1) WO2014145303A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180061226A (ko) 2015-09-11 2018-06-07 와이즈에이씨가부시키가이샤 항cd26 항체와 다른 항암제를 조합한 암 치료용 조성물
US10342797B2 (en) 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN108530511B (zh) * 2017-03-02 2021-06-22 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素衍生物
CN106946975B (zh) * 2017-03-16 2020-08-14 上海天氏利医药科技有限公司 一种雷公藤甲素衍生物及其制备方法与制剂
CN106994129A (zh) * 2017-05-15 2017-08-01 王晓辉 雷公藤甲素及其衍生物在制备治疗和/或预防肺损伤疾病的药物中的应用
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN109771430A (zh) * 2019-03-15 2019-05-21 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
CN111494319A (zh) * 2020-06-15 2020-08-07 沈阳药科大学 雷公藤甲素复方组合物及其制备方法与应用
CN115466269A (zh) * 2021-06-11 2022-12-13 复旦大学 一种胆碱碳酸酯类前药及其制备方法和应用
CN114569554A (zh) * 2022-03-01 2022-06-03 福建省医学科学研究院 一种肿瘤靶向性雷公藤内酯醇乳液及其制备方法
CN114831962A (zh) * 2022-04-29 2022-08-02 福建省医学科学研究院 一种雷公藤内酯醇固体脂质纳米粒及其滴丸的制备方法
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3631795A (en) * 1994-09-15 1996-03-29 Pharmagenesis, Inc. Composition and method for immunotherapy
WO2004058246A1 (en) * 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
ES2385716T3 (es) * 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
EP1933856A4 (en) * 2005-08-29 2008-11-19 Sepsicure L L C METHOD OF TREATING OR PREVENTING CONDITIONS INDUCED BY GRAM POSITIVE BACTERIA
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
CN102552137B (zh) * 2012-02-22 2013-04-10 福建医科大学 雷公藤内酯醇脂肪乳注射剂及其制备方法

Also Published As

Publication number Publication date
EP2968140A4 (en) 2016-11-16
US20160038454A1 (en) 2016-02-11
TW201440812A (zh) 2014-11-01
JP2016515530A (ja) 2016-05-30
WO2014145303A1 (en) 2014-09-18
TWI597071B (zh) 2017-09-01
CN105263475A (zh) 2016-01-20
EP2968140A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1219228A1 (zh) 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
AU780284B2 (en) Immunosurpressive effects of pteridine derivatives
JP5057966B2 (ja) 免疫調節剤および抗癌剤としてのトリプトライドラクトン環誘導体
KR20170106304A (ko) 암-표적화 약물 운송수단으로서의 인지질 에테르 유사체
CA3130349A1 (en) Lipid prodrugs of jak inhibitors and uses thereof
JP4680589B2 (ja) アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
CN107708686B (zh) 氧杂二环庚烷前药
WO2018157874A1 (zh) 一种双氢青蒿素二倍体衍生物、其药物组合物及应用
WO2019126378A1 (en) Lipid prodrugs of mycophenolic acid and uses thereof
RS60558B1 (sr) Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
CA3111403A1 (en) Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease
US7098348B2 (en) Triptolide derivatives as immunomodulators and anticancer agents
US20070244080A1 (en) Method for Treatment of Inflammatory Disorders Using Triptolide Compounds
EP4537847A2 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
JP2023517736A (ja) 免疫調節剤
CN105585569B (zh) 一种恩替卡韦脂肪酸衍生物及其药物组合物
KR101384634B1 (ko) 베르게닌 또는 베르게닌 유도체를 포함하는 마약중독 치료용 약학적 조성물
JP2016508489A (ja) プロトパナキサジオール誘導体、その製造方法及びその応用
JP2016504341A (ja) 過敏性腸症候群を治療するためのアルピニア種抽出物
WO2004026298A1 (en) Derivatives of triptolide having high immunosuppressive effect and high water solubility, and uses thereof
JP2023524813A (ja) 免疫調節剤
Walczak et al. Approaches towards better immunosuppressive agents
EP4126902B1 (en) Immunomodulators